<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103310</url>
  </required_header>
  <id_info>
    <org_study_id>14207</org_study_id>
    <nct_id>NCT01103310</nct_id>
  </id_info>
  <brief_title>Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation</brief_title>
  <official_title>Open-label, Multi Center Study for an Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 100 µg Total Quantity) in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability, Pharmacokinetics, and Diagnostic Performance of the Tracer in PET/CT in Cancer Patients or Patients With Inflammation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piramal Imaging SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Piramal Imaging SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography)
      images obtained after a single intravenous injection of BAY94-9392 in patients with cancer or
      inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual assessment of lesion</measure>
    <time_frame>Day of study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative analysis of BAY94-9392 uptake into lesions (Standardized Uptake Values = SUVs)</measure>
    <time_frame>Day of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>At least twice within 2 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>At least twice within 2 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum protein</measure>
    <time_frame>At least twice within 2 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>At least twice within 2 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum GOT (Glutamate-Oxalacetate-Transaminase)</measure>
    <time_frame>At least twice within 2 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>Continuously for at least 4 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation doses per organ (µGy/MBq)</measure>
    <time_frame>Day of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Higher organ dose (HT)</measure>
    <time_frame>Day of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses per organ (µSv/MBq)</measure>
    <time_frame>Day of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective dose (µSv/MBq)</measure>
    <time_frame>Day of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective dose resulting from the total administered diagnostic activity of 300 MBq +/- 10%</measure>
    <time_frame>Day of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Diagnostic Imaging</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY94-9392</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        In Germany Healthy volunteers

          -  Males/females ≥ 50 and ≤ 65 years Patients

          -  Males/females ≥ 35 and ≤ 75 years

          -  histologically confirmed diagnosis of non small cell lung cancer or adenocarcinoma of
             the breast with a positive FDG-PET or

          -  patient with primary prostate cancer scheduled for prostatectomy and patient with
             prostate tumor recurrence with a positive choline-PET, the initial disease is
             histologically confirmed or

          -  inflammation with a positive FDG-PET

        In Korea Patients

          -  Males/females ≥ 35 and ≤ 75 years

          -  histologically confirmed diagnosis of non small cell lung cancer, adenocarcinoma of
             the breast or hepatocellular cancer with a positive FDG-PET or

          -  patient with primary prostate cancer scheduled for prostatectomy and patient with
             prostate tumor recurrence with a positive choline-PET, the initial disease is
             histologically confirmed or

          -  inflammation (positive FDG-PET mandatory, could be also done as screening examination)

        Exclusion criteria:

          -  Concurrent severe and/or uncontrolled and/or unstable medical disease other than
             cancer or inflammation (e.g. poorly controlled diabetes, congestive heart failure,
             myocardial infarction within 12 months prior to planned injection of BAY 94-9392,
             unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe
             pulmonary disease) which could compromise participation in the study

          -  Known sensitivity to the study drug or components of the preparation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <reference>
    <citation>Baek S, Mueller A, Lim YS, Lee HC, Lee YJ, Gong G, Kim JS, Ryu JS, Oh SJ, Lee SJ, Bacher-Stier C, Fels L, Koglin N, Schatz CA, Dinkelborg LM, Moon DH. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. J Nucl Med. 2013 Jan;54(1):117-23. doi: 10.2967/jnumed.112.108704. Epub 2012 Dec 11.</citation>
    <PMID>23232273</PMID>
  </reference>
  <reference>
    <citation>Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, Oh SJ, Bacher-Stier C, Fels L, Koglin N, Hultsch C, Schatz CA, Dinkelborg LM, Mittra ES, Gambhir SS, Moon DH. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res. 2012 Oct 1;18(19):5427-37. doi: 10.1158/1078-0432.CCR-12-0214. Epub 2012 Aug 14.</citation>
    <PMID>22893629</PMID>
  </reference>
  <reference>
    <citation>Smolarz K, Krause BJ, Graner FP, Wagner FM, Hultsch C, Bacher-Stier C, Sparks RB, Ramsay S, Fels LM, Dinkelborg LM, Schwaiger M. (S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry. J Nucl Med. 2013 Jun;54(6):861-6. doi: 10.2967/jnumed.112.112581. Epub 2013 Apr 8.</citation>
    <PMID>23568366</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm</keyword>
  <keyword>PET/CT diagnosis</keyword>
  <keyword>PET tracer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

